India’s Universal Immunisation Programme (UIP) – Analytical Overview & Case for Introducing Hepatitis-A Vaccine
1. Introduction
India’s Universal Immunisation Programme (UIP), launched in 1985, is one of the largest public-health programmes in the world. It provides free vaccination against vaccine-preventable diseases (VPDs) to infants, children, and pregnant women. As disease patterns evolve due to improved sanitation and demographic shifts, the programme needs continuous scientific updating. The current national debate focuses on adding Hepatitis-A vaccine to UIP due to rising disease burden in adolescents and adults.
India's Universal Immunization Program (UIP) includes vaccines against 12 diseases: Diphtheria, Pertussis, Tetanus, Polio, Measles, Rubella, severe childhood Tuberculosis, Hepatitis B, Rotavirus diarrhea, Pneumococcal pneumonia, Meningitis & Pneumonia caused by Haemophilus influenzae type b (Hib), and Japanese Encephalitis (in select areas). Vaccines are provided free of charge to protect children from these diseases.
2. Constituents of UIP
| Component | Details |
|---|---|
| Target Group | ~2.7 crore newborns & ~2.6 crore pregnant women annually |
| Vaccines Covered | 12 vaccines, including BCG, OPV/IPV, DPT, Hep-B, Hib, Rotavirus, MR, JE (endemic states), PCV |
| Delivery System | Fixed outreach sessions, sub-centres, PHCs, CHCs, district hospitals |
| Support System | Cold-chain network, logistics management, digital tracking & AEFI monitoring |
| Technical Oversight | National Technical Advisory Group on Immunization (NTAGI) |
| Funding | Centre-State shared funding |
3. Major Achievements
-
Polio eradication (2014)
-
Sharp decline in measles mortality
-
Mission Indradhanush improved coverage significantly (Goal: 90% full immunisation)
-
Indigenous vaccine development reduced costs & improved access (e.g., Rotavirus, Covaxin)
-
Improvement in cold-chain capacity with monitoring technologies
4. Challenges in UIP
| Area | Key Issues |
|---|---|
| Coverage Gaps | Urban-poor, migrant population, remote tribal areas still under-covered |
| Delayed Vaccine Introduction | Slow decision-making on new vaccines (TCV, Hep-A) |
| Data Quality Issues | Variations between survey & administrative coverage |
| Vaccine Hesitancy | Rumours, misinformation, cultural barriers |
| Workforce & Logistics | Overburdened health staff, cold-chain management, training gaps |
| Financing | Competing priorities & limited state-level budget space |
5. Why Hepatitis-A Vaccine Needs Priority
Changing disease pattern
-
Earlier, most Indian children were infected in early childhood → mild disease → lifelong immunity.
-
Due to improved sanitation, exposure in childhood has reduced.
-
Now many teenagers & adults lack antibodies, making infection more severe.
Health Impact
-
Increasing outbreaks reported in Kerala, Maharashtra, UP, and Delhi.
-
Higher incidence of acute liver failure in older children/adults.
-
No specific treatment available—only supportive care.
Vaccine Science
| Parameter | Hepatitis-A Vaccine |
|---|---|
| Type | Live-attenuated / Inactivated |
| Efficacy | 90–95% |
| Protection duration | 15–20 years or lifelong |
| Doses | Single dose (live) or two-dose schedule |
| Advantages | Safe, long-lasting, no antibiotic resistance issues |
Indigenous Capability
-
India already manufactures high-quality HAV vaccines (e.g., live-attenuated Biovac-A).
-
Strong domestic manufacturing means lower cost and sustainable supply.
Cost-Effectiveness
-
Prevents high-cost hospitalization for liver complications.
-
Strong economic justification for inclusion in UIP.
Programmatic Feasibility
-
Can be co-administered with DPT/MR boosters.
-
Introduce first in high-burden states, then scale nationally.
6. Hepatitis-A vs Typhoid (TCV) – Comparative Perspective
| Criteria | Hep-A | Typhoid |
|---|---|---|
| Severity Trends | Increasing in adolescents/adults | Declining with antibiotics |
| Carrier state | None | Carrier possible |
| Resistance concerns | None | AMR rising |
| Vaccine durability | Long-lasting | Booster uncertainty |
| Rollout feasibility | Easier | Higher cost & complexity |
7. Government Initiatives & Future Roadmap
Key Ongoing Initiatives
-
Mission Indradhanush & Intensified MI
-
Strengthening AEFI and real-time cold-chain temperature tracking
-
Digital immunisation registries & eVIN system
-
Local vaccine R&D and Make-in-India platforms
Way Forward
-
Phased introduction of Hep-A vaccine starting with outbreak-prone states
-
State-specific serosurveys to assess immunity levels
-
Financing framework for new-vaccine expansion
-
Integrate with WASH (Water-Sanitation-Hygiene) programmes
-
Strengthen community awareness to tackle hesitancy
8. Conclusion
UIP remains a landmark of India’s public health transformation. However, evolving disease epidemiology demands dynamic decision-making. Given rising Hepatitis-A burden, high vaccine efficacy, indigenous manufacturing, and cost-effectiveness, its inclusion in UIP deserves priority. A carefully phased, evidence-based rollout will enhance public health outcomes and move India closer to Universal Health Coverage and SDG-3.
Value-Addition Points for UPSC
-
India has the world’s largest immunisation programme, covering over 3 crore beneficiaries annually.
-
Mission Indradhanush significantly improved coverage from ~62% to ~76%.
-
Major exam themes: AMR, cost-effectiveness of vaccines, indigenous R&D, disease transition due to sanitation, cold-chain infrastructure.
Comments
Post a Comment